Learn more about Elsevier’s Drug Patient Education today! Empower and engage your patients to use medication safely.
PEMBROLIZUMAB (PEM broe LIZ ue mab) treats some types of cancer. It works by helping your immune system slow or stop the spread of cancer cells. It is a monoclonal antibody.
This medication is injected into a vein. It is given by your care team in a hospital or clinic setting.
A special MedGuide will be given to you before each treatment. Be sure to read this information carefully each time.
Talk to your care team about the use of this medication in children. While it may be prescribed for children as young as 6 months for selected conditions, precautions do apply.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
This medication is given in a hospital or clinic. It will not be stored at home.
They need to know if you have any of these conditions:
Interactions have not been studied.
Keep appointments for follow-up doses. It is important not to miss your dose. Call your care team if you are unable to keep an appointment.
Your condition will be monitored carefully while you are receiving this medication. You may need blood work while taking this medication.
This medication may cause serious skin reactions. They can happen weeks to months after starting the medication. Contact your care team right away if you notice fevers or flu-like symptoms with a rash. The rash may be red or purple and then turn into blisters or peeling of the skin. You may also notice a red rash with swelling of the face, lips, or lymph nodes in your neck or under your arms.
Tell your care team right away if you have any change in your eyesight.
Talk to your care team if you may be pregnant. Serious birth defects can occur if you take this medication during pregnancy and for 4 months after the last dose. You will need a negative pregnancy test before starting this medication. Contraception is recommended while taking this medication and for 4 months after the last dose. Your care team can help you find the option that works for you.
Do not breastfeed while taking this medication and for 4 months after the last dose.
Cookies are used by this site. To decline or learn more, visit our cookie notice.